Alvotech was founded in 2013 by the Chairman, Robert Wessman. His initial strategy was to invest in the development and manufacture of a portfolio of biosimilar monoclonal antibodies and to build a state-of-the-art manufacturing facility in Reykjavik Iceland since then, the investment commitment has increased to more than $600 million and Alvotech has established itself as a key player and up-and-coming powerhouse in the biosimilar space.
2019
Business
Alvotech completes US$300 million financing deal through a private bond offering
Global
Work begins on Alvotech-CCHN joint venture in China
Product
Alvotech enrolls first patient in clinical phase III study involving biosimilar version of HUMIRA®
Global
Alvotech and Fuji Pharma announce exclusive partnership agreement to commercialize Alvotech’s ustekinumab biosimilar (Stelara®) in Japan
People
Mark Levick appointed CEO of Alvotech
2018
Iceland
Manufacturing licensure granted by the Icelandic Medicines Agency, in consultation with the Irish Health Products Regulatory Authority for our biopharmaceutical facility in Reykjavik, Iceland
Portfolio
Agreement with Changchun High & New Technology Industries Group Inc (“CCHN”) which will enable Alvotech to develop, manufacture and commercialize its biosimilar portfolio in China
2017
Business
One biosimilar selection to bring pipeline to seven assets
Business
Acquisition of Glycothera in Hanover, Germany adding further analytical capabilities and expertise
2016
Product
Next two biosimilars selected to bring pipeline to six assets
Research
Acquisition of development arm of Baliopharm GmbH to further strengthen our R&D platform
Business
Manufacturing facility undergoing first inspection
Business
Inauguration of our Icelandic facility
2015
Business
Continuing product development and facility establishment build-up of capacity and staff
2014
Products
Development of next two product candidates initiated, bringing pipeline to four biosimilars
Partnership
Partnership agreement with a global pharma company signed
2013
Business
Founding of Alvotech and start of development for the first two biosimilars
Business
Breaking ground on state-of-the-art, 13,278 squaremeters single use biomanufacturing facility in Reykjavik, Iceland
Business
Strategic investments to increase R&D capabilities